Boost for GSK
GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
GSK PLC GSK shares rose 2.90% to £13.83 Monday, on what proved to be an all-around great trading session for the stock market ...
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...
As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.
FOR IMMEDIATE RELEASERelation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and ...
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback